Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia (Post-authorization safety study in type 2 diabetic)

25/07/2017
16/10/2026
EU PAS number:
EUPAS20025
Study
Finalised
Documents
Study protocol
Updated protocol
English (14.87 MB - PDF) View document
English (474.85 KB - PDF) View document
Study results
Study results
English (364.89 KB - PDF) View document
Study report
No information provided.
ENCePP Seal
No information provided.